{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:38:33Z","timestamp":1783485513129,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.canep.2013.10.004","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T13:47:04Z","timestamp":1383313624000},"page":"870-875","source":"Crossref","is-referenced-by-count":41,"title":["Spironolactone use and the risk of breast and gynecologic cancers"],"prefix":"10.1016","volume":"37","author":[{"given":"Robert J.","family":"Biggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth W.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wohlfahrt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Melbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2013.10.004_bib0005","first-page":"198","article-title":"Potassium-sparing diuretics","volume":"10","author":"Horisberger","year":"1987","journal-title":"Ren Physiol"},{"key":"10.1016\/j.canep.2013.10.004_bib0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1210\/jcem-46-2-338","article-title":"Interaction of digitalis and spironolactone with human sex steroid receptors","volume":"46","author":"Rifka","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.canep.2013.10.004_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00003081-197506000-00006","article-title":"Drugs that affect the breast and lactation","volume":"18","author":"Dickey","year":"1975","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.canep.2013.10.004_bib0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1056\/NEJM199302183280708","article-title":"Gynecomastia","volume":"328","author":"Braunstein","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2013.10.004_bib0025","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.canep.2013.10.004_bib0030","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4065\/84.8.672","article-title":"Male Gynecomastia","volume":"84","author":"Bridgett","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.canep.2013.10.004_bib0035","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0968-0896(98)00260-0","article-title":"Spironolactone-related inhibitors of type II 17\u03b2-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative\/antiproliferative activities","volume":"7","author":"Tremblay","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.canep.2013.10.004_bib0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0960-0760(02)00154-1","article-title":"On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production","volume":"82","author":"Satoh","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.canep.2013.10.004_bib0045","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-11-1389","article-title":"Molecular pathways: digoxin use and estrogen-sensitive cancers\u2014risks and possible therapeutic implications","volume":"18","author":"Biggar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canep.2013.10.004_bib0050","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/bcr2205","article-title":"Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case control study","volume":"10","author":"Ahern","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canep.2013.10.004_bib0055","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2010.32.8146","article-title":"Digoxin use and the risk of breast cancer in women","volume":"29","author":"Biggar","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canep.2013.10.004_bib0060","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ijc.26424","article-title":"Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix","volume":"131","author":"Biggar","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canep.2013.10.004_bib0065","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(75)92814-7","article-title":"Letter: breast cancer and spironolactone","volume":"2","author":"Jick","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2013.10.004_bib0070","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(75)92645-8","article-title":"Letter: breast cancer associated with administration of spironolactone","volume":"1","author":"Loube","year":"1975","journal-title":"Lancet."},{"key":"10.1016\/j.canep.2013.10.004_bib0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10147-003-0372-2","article-title":"Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy","volume":"9","author":"Lamy","year":"2004","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.canep.2013.10.004_bib0080","series-title":"IARC monographs on the evaluation of carcinogenic risks to humans, vol. 79. Some thyrotropic agents. Spironolactone","first-page":"321","author":"IARC","year":"2001"},{"issue":"345","key":"10.1016\/j.canep.2013.10.004_bib0085","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study","volume":"13","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.canep.2013.10.004_bib0090","first-page":"460","article-title":"Furosemide (frusemide). Pharmacokinetic\/pharmacodynamic review (Part II)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.canep.2013.10.004_bib0095","first-page":"445","article-title":"The Danish prescription registries","volume":"44","author":"Gaist","year":"1997","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.canep.2013.10.004_bib0100","first-page":"535","article-title":"The Danish Cancer Registry\u2014history, content, quality, and use","volume":"44","author":"Storm","year":"1997","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.canep.2013.10.004_bib0105","series-title":"International classification of diseases for oncology","author":"World Health Organization","year":"2000"},{"key":"10.1016\/j.canep.2013.10.004_bib0110","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1471-0528.2005.00572.x","article-title":"Symptoms associated with diagnosis of ovarian cancer: a systematic review","volume":"112","author":"Bankhead","year":"2005","journal-title":"BJOG"},{"key":"10.1016\/j.canep.2013.10.004_bib0115","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/01.AOG.0000260392.70365.5e","article-title":"Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer","volume":"109","author":"Ryerson","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.canep.2013.10.004_bib0120","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","article-title":"Frequency of symptoms of ovarian cancer in women presenting to primary care clinics","volume":"291","author":"Goff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2013.10.004_bib0125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.2010.05652.x","article-title":"Diagnosis and management of hirsutism","volume":"1205","author":"Escobar-Morreale","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.canep.2013.10.004_bib0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2007-961807","article-title":"Sexual hormones in human skin","volume":"39","author":"Zouboulis","year":"2007","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.canep.2013.10.004_bib0135","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4158\/EP11117.RA","article-title":"The hirsute woman: challenges in evaluation and management","volume":"17","author":"Paparodis","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.canep.2013.10.004_bib0140","first-page":"328","article-title":"Use of spironolactone in dermatology","volume":"8","author":"Rathnayake","year":"2010","journal-title":"Skinmed"},{"key":"10.1016\/j.canep.2013.10.004_bib0145","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10552-010-9658-7","article-title":"Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study","volume":"21","author":"Fearnley","year":"2010","journal-title":"Cancer Causes Control"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187778211300163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187778211300163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T23:23:08Z","timestamp":1539213788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187778211300163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S187778211300163X"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2013.10.004","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}